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Abstract
Background and Objective
Twenty per cent of chronic obstructive pulmonary disease (COPD) patients are readmitted
for acute exacerbation (AECOPD) within 30 days of discharge. The prognostic significance
of early readmission is not fully understood. The objective of our study was to estimate the
mortality risk associated with readmission for acute exacerbation within 30 days of dis-
charge in COPD patients.
Methods
The cohort (n = 378) was divided into patients readmitted (n = 68) and not readmitted (n =
310) within 30 days of discharge. Clinical, laboratory, microbiological, and severity data
were evaluated at admission and during hospital stay, and mortality data were recorded at
four time points during follow-up: 30 days, 6 months, 1 year and 3 years.
Results
Patients readmitted within 30 days had poorer lung function, worse dyspnea perception and
higher clinical severity. Two or more prior AECOPD (HR, 2.47; 95% CI, 1.51–4.05) was the
only variable independently associated with 30-day readmission. The mortality risk during
the follow-up period showed a progressive increase in patients readmitted within 30 days in
comparison to patients not readmitted; moreover, 30-day readmission was an independent
risk factor for mortality at 1 year (HR, 2.48; 95% CI, 1.10–5.59). In patients readmitted within
30 days, the estimated absolute increase in the mortality risk was 4% at 30 days (number
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needed to harm NNH, 25), 17% at 6-months (NNH, 6), 19% at 1-year (NNH, 6) and 24% at
3 years (NNH, 5).
Conclusion
In conclusion a readmission for AECOPD within 30 days is associated with a progressive
increased long-term risk of death.
Introduction
In the natural course of Chronic Obstructive Pulmonary Disease (COPD), many patients expe-
rience acute exacerbations (AECOPD), characterized by an increase in systemic inflammatory
activity [1] and by a deterioration of their respiratory signs and symptoms [2]. The rate of
AECOPD becomes more frequent across disease severity [3]. However, some patients have an
increased risk of acute recurrence or relapse following the initial episode [4], linked to
increased susceptibility to exacerbations [5,6].
In general, COPD patients with higher rate of acute exacerbations have a greater annual
decline in lung function [7] and present poorer clinical outcomes [5,6,8]. With regard to prog-
nosis, previous studies have demonstrated that AECOPD represents an independent risk of
death due to all causes [8], regardless of the level of lung function impairment [9]. In one long-
term evaluation, the mortality risk was strictly related to the number of AECOPD episodes [10].
Hospital readmissions in COPD patients are known to have clinical and socioeconomic
consequences, especially if they are necessary soon after discharge (for example, within 30
days) [11]. Although the majority of readmissions in COPD patients are not respiratory-related
[12], around 20% are readmitted due to AECOPD within 30 days after discharge [13].
Although several predictors have been identified [14,15] and certain interventions have been
proposed [16] there is not enough evidence at present to recommend a single disease-specific
approach to address the problem [12,16].
To date, no studies have evaluated readmission for AECOPD within 30 days as a prognostic
factor in COPD patients. The aim of this study was therefore to estimate, in both short and
long-term follow-up periods, the risk of death due to all causes in patients presenting an acute
exacerbation within 30 days of discharge and requiring re-hospitalization.
Material and Methods
Study Design and Patients Selection
This observational study was conducted at a university hospital in Spain (Hospital Clinic, Bar-
celona) over a period of 64 months between May 2009 and September 2014. The sampling
method was systematic and all AECOPD patients admitted to the hospital’s Respiratory
Department were considered for the study. The patients included had to meet criteria for
COPD according to the GOLD guidelines [17]. Spirometry was performed in the stable phase
of the disease and at least six months prior to hospital admission. Patients with a smoking his-
tory of 10 pack-years were considered as positive smokers.
The study protocol was approved by the Hospital Research and Ethics Committee (CEIC
2008/4106) and conducted in accordance with good clinical practices and the declaration of
Helsinki. Written informed consent was obtained from all the patients enrolled.
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Definitions
A worsening of the respiratory symptoms compared with preceding days which required a
change in home care medication was used as the criterion for defining AECOPD [2,17]. The
severity of the exacerbation was based on the respiratory symptoms/signs and the presence of
potential indications for hospitalization [17].
A follow-up visit at 30 days from discharge after the index hospitalization confirmed read-
mission, defined as a readmission due to a new occurrence of symptoms/signs of AECOPD,
using the same criteria [2]. Patients readmitted for reasons other than AECOPD were not
considered.
Exclusion Criteria
At hospitalization index and at readmission to hospital, the exclusion criteria concerned
patients with a documented history of concomitant chronic respiratory condition (asthma and
bronchiectasis), patients with a suspected underlying malignancy, and patients in whom com-
munity-acquired pneumonia (CAP) and acute heart failure were identified clinically and by
means of chest x-ray.
Microbiological Sample Collection
Sputum from patients was obtained from spontaneous cough on the first day of admission to
hospital; an adequate sample, containing a count of more than 25 leukocytes and less than 10
epithelial cells per field, was processed using Gram stain and sputum culture. Inhalation of a
5% hypertonic saline solution for 5 to 10 minutes, delivered via a nebulizer device, was used to
obtain induced sputum production when spontaneous sputum samples were not obtainable.
Clinical Measurements and Outcomes
Data on demographic variables, body mass index (BMI), smoking habit, presence of co-morbid-
ities measured by Charlson Index, prevalence of ischemic heart disease and diabetes, baseline
dyspnea grade as per modified medical research council (mMRC), COPD severity score mea-
sured by a questionnaire COPDSS, use of long-term oxygen therapy (LTOT) and use of domicil-
iary medications (inhaled bronchodilators as short-acting β2 agonist [SABA], long-acting β2
agonist [LABA], and anticholinergics, inhaled corticosteroids) were recorded on admission to
hospital. Characteristics of exacerbations occurring in the preceding year were also recorded.
Vital signs (body temperature, respiratory and heart rate, systolic and diastolic blood pres-
sure) were assessed at admission. Gas analysis variables (pH, partial arterial carbon dioxide
pressure [PaCO2], the ratio of partial arterial oxygen pressure to the fraction of inspired oxygen
[PaO2/FiO2], serum bicarbonate [HCO3
-], base excess [BE]), and systemic inflammatory vari-
ables (leukocytes, haematocrit, haemoglobin, C-reactive protein [CRP], glucose, and creatinine
were recorded at admission and at day 3.
Variables relating to clinical progression included length of stay in hospital (LOS), use of
noninvasive and invasive mechanical ventilation (NIMV and IMV), and intensive care unit
(ICU) admission recorded during the initial hospitalization. Data on prognosis (cumulative
number of deaths for all-causes, time to death) were recorded in a follow-up period of 30 days,
6 months, 1 year and 3 years; centralized registries were used to identify the date of death.
Statistical Analysis
Table 1 shows number of patients (%) for categorical variables, and medians (1st quartile; 3rd
quartile) for continuous variables with non-normal distribution or means ±SD for those with
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normal distribution. Categorical variables were compared using the χ2 test or the Fisher exact
test and continuous variables with the t test or the nonparametric Mann-Whitney test. Univari-
ate and multivariate Cox proportional hazard regression analyses [18] were performed to iden-
tify variables associated with 30-day readmission (the dependent variable). The variables
included in the univariate analysis were: age, gender, BMI, smoking habit, respiratory rate,
heart rate, temperature, systolic and diastolic blood pressure, number of exacerbations, number
of exacerbations requiring hospitalization, number of days prior to exacerbation, COPD-SS,
Charlson index, mMRC dyspnea score, FEV1, FVC, CRP at admission, glucose at admission,
creatinine at admission, leukocytes at admission, haematocrit at admission, haemoglobin at
Table 1. General characteristics of study cohort.
Variables Cohort of patients
(N = 378)
Patients with 30-day
readmission* (N = 68)
Patients without 30-day
readmission* (N = 310)
p value
Age, years 71.4 ± 10 72.2 ± 10.6 71.2 ± 9.9 0.475
Male 318 (84) 60 (88) 258 (83) 0.306
BMI, kg/m2 27.4 ± 5.4 27.3 ± 5.2 27.4 ± 5.4 0.915
Smoking habit: Current/ No or Former,% 39/61 25/75 42/58 0.009
FEV1,% predicted † 44.2 ± 16.9 39.2 ± 14 45.3 ± 17.3 0.005
FEV1/FVC † 48.6 ± 14.4 46.8 ± 14.8 49 ± 14.4 0.299
GOLD stage: A/B/C/D,% 3/30/48/19 0/17/60/23 3/33/45/19 0.046
LTOT 104 (28) 32 (47) 72 (23) <0.001
mMRC baseline dyspnea grade 2 (1; 3) 3 (2; 3) 2 (1; 3) 0.013
COPDSS severity questionnaire 13 (8; 19) 18 (13; 21) 12 (7; 18) <0.001
Charlson index 2 (1; 3) 2 (1; 4) 2 (1; 3) 0.130
Ischemic heart disease 26 (7) 2 (3) 24 (8) 0.059
Diabetes 91 (24) 20 (29) 71 (23) 0.262
No of exacerbations ‡ 0 (0; 1) 1 (0; 2) 0 (0; 1) <0.001
No of patients with 2 exacerbations ‡ 83 (22) 26 (39) 57 (19) <0.001
No of exacerbations requiring hospitalization ‡ 0 (0; 1) 0 (0; 1) 0 (0; 1) 0.044
No of patients with 1 exacerbations requiring
hospitalization ‡
114 (31) 27 (40) 87 (28) 0.056
No of previous days until exacerbation 4 (2; 7) 3 (2; 7) 4 (2; 7) 0.020
Use of home care medications
Salbutamol only 12 (4) 2 (3) 10 (4) >0.99
Anticholinergic only 18 (5) 4 (6) 14 (5) 0.772
LABA + Anticholinergic 4 (1) 0 (0) 4 (2) 0.584
LABA + ICS 9 (3) 1 (1) 8 (3) 0.691
Anticholinergic + ICS 5 (2) 1 (1) 4 (2) >0.99
LABA + Anticholinergic + ICS 109 (33) 16 (24) 93 (36) 0.059
Data are shown as number of patients (%), means ± SD or medians (1st quartile; 3rd quartile), unless otherwise stated. Percentages are calculated on
non-missing data.
Abbreviations: AECOPD: chronic obstructive pulmonary disease exacerbation; BMI, body mass index; FEV1, forced expiratory volume in the 1
st second;
FVC, forced vital capacity; LTOT, long-term oxygen therapy; mMRC, modiﬁed medical research council; COPDSS, COPD severity score questionnaire;
LABA, long-acting β2 agonist; ICS, inhaled corticosteroids.
* Since index hospitalization.
† Data evaluated at least 6 months prior to index hospitalization.
‡ In a period of 1 year prior to index hospitalization.
LABA includes salmeterol, formoterol and indacaterol; Anticholinergic includes ipratropium and tiotropium; and ICS includes budesonide and ﬂuticasone.
doi:10.1371/journal.pone.0150737.t001
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admission, pH at admission, PaCO2 at admission, PaO2/FiO2 at admission, ICU admission,
NIMV, IMV, and LOS.
Univariate and multivariate Cox proportional hazard regression analyses were also per-
formed to identify variables associated with 1-year mortality (dependent variable). The vari-
ables included in this univariate analysis were the ones mentioned above, plus 30-day
readmission. Variables that showed a significant result (p<0.1) were included in the corre-
sponding multivariate Cox proportional hazard regression backward stepwise model. Variables
that correlated strongly (r>|±0.3|) were excluded from the multivariate analyses. Unadjusted
and adjusted hazard ratios (HR) and 95% confidence intervals (CI) were calculated. Time-to-
event variables (30-day, 6-month, 1 year and 3-year mortality) were analyzed by means of
Kaplan-Meier survival curves (a Gehan-Breslow-Wilcoxon test was applied, because this test
emphasizes early differences [19]). Patients who were lost to follow-up were censored in the
survival analysis; moreover, in order to define potential survival bias, an analysis comparing
patients considered for the study and those lost to follow-up after one year was performed. We
also calculated the number needed to harm (NNH) [20] for the analyses involving 30-day read-
mission. This statistic represents the number of patients who would need to be readmitted for
one death to occur. All reported p values were two-sided and were not adjusted for multiple
comparisons. A p value less than 0.05 was considered significant. All analyses were performed
with IBM SPSS Statistics 20.0 (Armonk, New York, USA).
Results
Patient Characteristics
In total, 378 consecutive patients (84% men) with a mean±SD age of 71±10 years were admit-
ted to hospital for an AECOPD. Of these, 68 patients (18%) had a new AECOPD that required
hospitalization in the 30 days after discharge. Table 1 compares the characteristics of the
patients enrolled in the study and divided according to readmission/non-readmission within
30 days, and Fig 1 shows the study flow diagram.
Early readmitted patients presented greater severity according to functional, symptomatic
and questionnaire-reported characteristics of COPD than patients without 30-day readmis-
sion. Moreover, readmitted patients more frequent required LTOT and had a significant his-
tory of exacerbations in the previous year, also requiring hospitalization. No significant
differences were found for age, sex, BMI, presence of co-morbidities or use of home care
medication.
Clinical and Microbiological Variables
With regard to clinical (Table 2) and microbiological (Table 3) variables recorded at admission
and during the clinical course, patients with and without 30-day readmission showed differ-
ences only in terms of pH at day 3 (with lower values in readmitted patients), PaCO2 at admis-
sion (higher values), and haematocrit at day 3 (lower values). The other variables presented
similar values in the two groups.
Predictors of 30-Day Readmission Identified in Univariate and
Multivariate Analyses
Several variables were significantly associated with 30-day readmission in the univariate Cox
regression analyses (Table 4). In the multivariate analysis, a history of2 exacerbations in the
previous year (HR, 2.47; 95% CI, 1.51 to 4.05) was the only variable independently associated
with 30-day readmission.
30-Day Readmission for AECOPD and Mortality Risk
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Fig 1. Study flow diagram. Abbreviations: AECOPD: chronic obstructive pulmonary disease exacerbation.
doi:10.1371/journal.pone.0150737.g001
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Table 2. Clinical and laboratory variables recorded at admission and during clinical course of index hospitalization.
Variables Cohort of patients
(N = 378)
Patients with 30-day
readmission (N = 68)
Patients without 30-day
readmission (N = 310)
p
value
Vital signs
Respiratory rate, b/min 24 (20; 28) 24 (20; 28) 24 (20; 28) 0.952
Heart rate, b/min 93 (82; 105) 91.5 (80; 104) 94 (83; 105) 0.296
Temperature, °C 36.3 (36; 36.9) 36 (36; 36.6) 36.4 (36; 37) 0.085
SBP, mmHg 139 (123; 156) 138 (123; 158) 139 (126; 151) 0.842
DBP, mmHg 75.5 (68; 86) 76 (68; 87) 73 (68; 84) 0.096
Gas analysis and systemic inﬂammatory
variables
pH at admission 7.39 (7.34; 7.43) 7.38 (7.32; 7.43) 7.39 (7.34; 7.43) 0.121
pH at day 3 7.41 (7.38; 7.44) 7.38 (7.35; 7.41) 7.42 (7.39; 7.44) 0.002
PaCO2 at admission, mmHg 47.3 (38.6; 58.3) 51.0 (40.3; 65.6) 46.0 (38.5; 57.6) 0.048
PaCO2 at day 3, mmHg 48 (41.3; 54.4) 50.9 (41.1; 62) 47.4 (41.3; 53) 0.271
PaO2/FiO2 at admission, mmHg 262 (219; 315) 258 (226; 317) 263 (218; 314) 0.987
PaO2/FiO2 at day 3, mmHg 280 (251; 316) 280 (246; 312) 280 (256; 319) 0.517
HCO3 at admission, mmol/L 28 (24.7; 32.2) 29 (24.5; 34.2) 27.9 (24.7; 31.6) 0.369
HCO3 at day 3, mmol/L 30 (27; 34.1) 31 (26.8; 34.9) 29.8 (27; 33.4) 0.612
BE at admission, mmol/L 2.3 (-0.2; 5.6) 2.4 (-0.9; 6.8) 2.3 (-0.1; 5.2) 0.958
BE at day 3, mmol/L 4.6 (2.2; 7.5) 5.1 (1.5; 8.8) 4.5 (2.6; 7.5) 0.977
Leucocytes at admission, x 109/l 10.4 (7.7; 14) 9.8 (8.1; 14.6) 10.4 (7.7; 14) 0.913
Leucocytes at day 3, x 109/l 10.6 (8.2; 13.2) 10.4 (7; 13.3) 10.7 (8.3; 13.1) 0.442
Haematocrit at admission,% 43 (40; 47) 42.5 (40; 45.5) 44 (39; 47) 0.140
Haematocrit at day 3,% 40 (37; 44) 39.5 (36; 42.5) 41 (37; 45) 0.045
Haemoglobin at admission, g/L 139 (126; 152) 136 (125.5; 147.5) 140 (126; 153) 0.142
Haemoglobin at day 3, g/L 131 (118; 142) 126 (118.5; 136.5) 132 (118; 143) 0.067
C-reactive protein at admission, mg/dL 3.8 (1.3; 10.4) 3.2 (1.4; 8) 3.9 (1.3; 10.5) 0.272
C-reactive protein at day 3, mg/dL 1.2 (0.4; 3.6) 1.8 (0.4; 4.3) 1.1 (0.4; 3.4) 0.366
Glucose at admission, mg/dL 125 (107; 159) 125.5 (104; 165.5) 124 (107; 155) 0.933
Glucose at day 3, mg/dL 119 (97; 157) 126 (103.5; 162.5) 116 (96; 154) 0.064
Creatinine at admission, mg/dL 0.9 (0.8; 1.1) 0.9 (0.8; 1.2) 0.9 (0.8; 1.1) 0.624
Creatinine at day 3, mg/dL 0.9 (0.7; 1.2) 0.9 (0.8; 1.2) 0.9 (0.7; 1.1) 0.681
No of patients using systemic corticosteroids
(Methylprednisolone)
342 (92) 65 (97) 277 (91) 0.092
No of patients using antibiotics 311 (88) 58 (89) 253 (87) 0.660
Duration of antibiotic treatment, days 7 (5; 10) 7 (5; 10) 7 (5; 10) 0.964
Classes of antibiotics used
Penicillins (Amoxicillin, Amoxicillin/Clavulanate) 53 (18) 10 (17) 43 (18) 0.945
Fluoroquinolones (Ciproﬂoxacin, Moxiﬂoxacin,
Levoﬂoxacin)
156 (52) 28 (48) 128 (52) 0.567
Macrolides (Azithromycin, Clarithromycin) 6 (2) 2 (3) 4 (2) 0.325
Cefalosporins (Ceftriaxone, Cefotaxime,
Cefuroxime and Cefepime)
10 (3) 4 (7) 6 (2) 0.090
Carbapenems (Meropenem) 1 (0.3) 0 (0) 1 (0.4) >0.99
Data are shown as number of patients (%) or median (1st quartile; 3rd quartile), unless otherwise stated. Percentages are calculated on non-missing data.
Abbreviations: SBP and DBP indicate systolic and diastolic blood pressure respectively; PaCO2, partial arterial carbon dioxide pressure; PaO2/FiO2, ratio
of partial arterial oxygen pressure to the fraction of inspired oxygen; HCO3, serum bicarbonate; BE, base excess.
doi:10.1371/journal.pone.0150737.t002
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Outcomes
Patients with a 30-day readmission had a longer median hospital stay than patients not read-
mitted (9 [6.5; 13] vs. 7 [5; 10] days, p = 0.003); no significant differences were found between
the groups with regard to the use of NIMV and IMV or for ICU admission. The overall mortal-
ity after 30 days differed between readmitted and non-readmitted patients (5% vs. 1%,
p = 0.045). Mortality evaluated after the follow-up periods of 6 months, 1 year and 3 years was
also higher in the group of patients readmitted within 30 days (27% vs. 10%, p<0.001; 37% vs.
17%, p = 0.001; and 67% vs. 43% respectively, p = 0.001) and their periods of survival were
shorter (109 vs. 162 days, p = 0.021; 124 vs. 209 days, p = 0.014; 250 vs. 445 days respectively,
p = 0.023) (Table 5). In patients readmitted within 30 days, the estimated absolute increase in
mortality risk was 4% at 30 days (NNH, 25; 95% CI, 8–243), 17% at 6 months (NNH, 6; 95%
CI, 3–14), 19% at 1 year (NNH, 6; 95% CI, 3–13) and 24% at 3 years (NNH, 5; 95% CI, 3–11)
(Table 6). All patients were followed up for survival. Before the corresponding follow-up
period, only the data for the patients who were lost to follow-up were censored (on the date
when they were last known to be alive). The comparison of general characteristics between
patients followed for 1 year and lost (Table 7) did not show any significant variables potentially
influencing the risk of death. Kaplan-Meier survival curves depicting death rates as a function
of 30-day readmission are shown in Fig 2. In the four Kaplan Meier curves obtained at different
periods of follow-up, the risk of death in patients readmitted within 30 days was higher than in
Table 3. Microbiological variables.
Patients with a 30-day readmission
(N = 68)
Patients without a 30-day readmission
(N = 310)
p
value
Patients with positive cultures in sputum 17 (25) 62 (20) 0.358
Polymicrobial etiology 1 (6) 6 (10) >0.99
Streptococcus spp. 3 (18) 14 (23) >0.99
Pseudomonas aeruginosa 7 (41) 14 (23) 0.135
Streptococcus pneumoniae 1 (6) 6 (10) >0.99
Moraxella catarrhalis 1 (6) 1 (2) 0.386
Haemophilus inﬂuenzae 0 (0) 12 (19) 0.060
Staphylococcus spp 2 (12) 2 (3) 0.201
Serratia 1 (6) 0 (0) 0.215
Pasteurella 1 (6) 1 (2) 0.386
Mycobacterium no-TBC 0 (0) 1 (2) >0.99
Aspergilus 0 (0) 2 (3) >0.99
Candida spp 0 (0) 2 (3) >0.99
Patients positive for Inﬂuenza A/H1N1 in naso-
pharyngeal swab *
7 (21) 20 (13) 0.279
Inﬂuenza B virus 2 (29) 0 (0) 0.060
Respiratory syncytial virus 2 (29) 2 (10) 0.269
Rhinovirus 1 (14) 6 (30) 0.633
Parainﬂuenza virus type 1 1 (14) 2 (10) >0.99
Parainﬂuenza virus type 3 0 (0) 2 (10) >0.99
Parainﬂuenza virus type 4 0 (0) 1 (5) >0.99
Data are shown as number of patients (%).
* Percentages are calculated on total patients with nasopharyngeal swab in each group (N = 33 and N = 150 in the groups of patients with and without
30-day readmission respectively).
doi:10.1371/journal.pone.0150737.t003
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patients not readmitted (Gehan-Breslow-Wilcoxon test p = 0.013, p<0.001, p<0.001, and
p<0.001 in the follow-up at 30 days [Fig 2, part A], 6 months [Fig 2, part B], 1 year [Fig 2, part
C] and 3 years [Fig 2, part D] respectively).
Predictors of 1-Year Mortality in the Multivariate Analysis
The multivariate Cox regression model with death at one year as a dependent variable
(Table 8) showed that a history of two or more exacerbations in the previous year (HR, 3.62;
95% CI, 1.70–7.70), increased dyspnea perception (reflected in an mMRC dyspnea score of 2
or more, HR, 4.71; 95% CI, 1.40–15.82), increased levels of PaCO2 (+1 mmHg; HR, 1.02; 95%
CI, 1.01–1.04), both evaluated at initial admission for the index hospitalization and at 30-day
readmission for AECOPD (HR, 2.48; 95% CI, 1.10–5.59) were independent significant predic-
tors of mortality.
Discussion
Our study found that COPD patients with an acute exacerbation requiring hospitalization
within 30 days of discharge have a subsequent progressive increase in the risk of death over
three years of follow-up, independently of the severity of airflow obstruction. Moreover, a his-
tory of two or more exacerbations in the previous year predicts readmission within a month of
discharge.
Table 4. Significant univariate andmultivariate Cox regression analyses predicting the probability of a 30-day readmission.
Variable Univariate Multivariate
HR 95% CI p value HR 95% CI p value
Age 70 y 1.72 1.01–2.92 0.045 - - -
Smoking habit * 0.026 - - -
No 1 - - - - -
Current 0.43 0.13–1.46 0.17 - - -
Former 0.90 0.28–2.90 0.87 - - -
Temperature (+1°C) 0.74 0.53–1.03 0.072 - - -
DBP (+1 mmHg) 0.98 0.96–1.00 0.056 - - -
No. of exacerbations 2 † 2.47 1.51–4.05 <0.001 2.47 1.51–4.05 <0.001
No. of previous days until exacerbation (+1 days) 0.93 0.87–0.99 0.017 - - -
COPD-SS 15 ‡ 2.68 1.62–4.45 <0.001 - - -
mMRC dyspnea score  2 ‡ 2.81 1.29–6.12 0.009 - - -
FEV1 <50% § 2.57 1.30–5.09 0.007 - - -
Haematocrit (+1%) ‡ 0.96 0.92–1.00 0.068 - - -
Haemoglobin (+1 g/L) ‡ 0.99 0.98–1.00 0.099 - - -
pH (+0.1 units) ‡ 0.73 0.54–0.98 0.033 - - -
PaCO2 (+1 mmHg) ‡ 1.02 1.00–1.03 0.009 - - -
LOS (+1 day) 1.04 1.01–1.07 0.003 - - -
* The p-value corresponds to differences between the three groups (non-smoker, current smoker, or former smoker).
† In a period of 1 year prior to index hospitalization.
‡ Evaluated at admission for index hospitalization index.
§ Data evaluated at least 6 months prior to index hospitalization.
Abbreviations: see Tables 1, 2 and 5.
doi:10.1371/journal.pone.0150737.t004
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In the comparison of baseline characteristics between patients with and without a 30-day
readmission for AECOPD, several variables differed between the two groups (lower predicted
FEV1%, greater prevalence of GOLD stages C and D, greater prevalence of LTOT, higher per-
ceived level of dyspnea [mMRC score], and a higher score on the COPD severity score ques-
tionnaire). In addition, we found that two or more prior AECOPD recorded in the year prior
to the index event was an independent predictor of a new readmission within 30 days of dis-
charge. This finding, corroborate the hypothesis of a specific susceptibility to exacerbation in
some COPD patients [5,6], reported in previous studies which showed that a history of previ-
ous events was the most important predictor of subsequent exacerbations [13,21]. As reported
elsewhere [13], microbiological and early inflammatory patterns at admission did, not differ
and did not affect the likelihood of AECOPD within 30 days of discharge.
Table 5. Study Outcomes.
Cohort of patients
(N = 378)
Patients with 30-day readmission
(N = 68)
Patients without 30-day readmission
(N = 310)
p
value
LOS, days 8.7 ± 5.6 8 (6; 10) 10.4 ± 6.7 9 (6.5; 13) 8.3 ± 5.3 7 (5; 10) 0.003
NIMV 82 (22) 17 (25) 65 (21) 0.473
IMV 14 (4) 3 (4) 11 (4) 0.724
ICU admission 45 (12) 8 (12) 37 (12) >0.99
30-day mortality 5 (1) 3 (5) 2 (1) 0.045
Time to death
(days)
28.8 ± 2.2 30 (29; 30) 28 ± 2.7 29 (25; 30) 30 ± 0 30 (30; 30) 0.20
6-month mortality 44 (13) 17 (27) 27 (10) <0.001
Time to death
(days)
124.5 ± 52.6 127 (78;
182.5)
101.2 ± 52.6 109 (56; 139) 139.1 ± 47.9 162 (86; 182.5) 0.021
1-year mortality 71 (21) 23 (37) 48 (17) 0.001
Time to death
(days)
204.3 ± 109.4 198 (109;
313)
157 ± 106.9 124 (66; 237) 223.9 ± 104.4 209 (143; 332) 0.014
3-year mortality * 133 (48) 37 (67) 96 (43) 0.001
Time to death
(days)
470.5 ± 324.4 406 (189;
739)
382 ± 326.6 250 (111; 648) 504.6 ± 318.7 445 (209; 748.5) 0.023
Data are shown as number of patients (%), mean ± SD or median (1st quartile; 3rd quartile), unless otherwise stated. Percentages are calculated on non-
missing data.
Abbreviations: LOS indicates length of stay in hospital; NIMV and IMV, noninvasive and invasive mechanical ventilation; ICU, intensive care unit.
* Percentages calculated on patients in the follow-up at 3 years (N = 55 and N = 222 in the group of patients with and without a 30-day readmission
respectively).
doi:10.1371/journal.pone.0150737.t005
Table 6. The relative risks, absolute relative risks and number needed to harm of the events (mortality in the follow-up period at30 days, 6 months,
1 year and 3 years).
Estimate of RR [95%CI] Estimate of ARR [95%CI] Estimate of NNH [95%CI]
30-day mortality 6.67 [1.14 to 39.07] -0.04 * [-0.12 to -0.004] 25 † [8 to 243]
6-month mortality 2.80 [1.63 to 4.81] -0.17 [-0.30 to -0.07] 6 [3 to 14]
1-year mortality 2.13 [1.41 to 3.23] -0.19 [-0.32 to -0.08] 6 [3 to 13]
3-year mortality 1.56 [1.23 to 1.97] -0.24 [-0.37 to -0.09] 5 [3 to 11]
* Sample interpretation: in patients with a 30-day readmission, the estimated absolute increase in mortality risk at 30 days was 4%.
† Sample interpretation: for every 25 patients readmitted, one death was caused within 30 days.
Abbreviations: RR, relative risk; CI, conﬁdence interval; ARR, absolute relative risk; NNH, number needed to harm.
doi:10.1371/journal.pone.0150737.t006
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With regard to outcomes, hospital length of stay (LOS), was clearly higher in severe read-
mitted patients, but it was interesting to see that the use of NIMV and IMV and the number of
ICU admissions were comparable between groups. This confirms the similar degree of
AECOPD severity at the index hospitalization. In our short and long-term evaluation, however,
30-day readmission for AECOPD predicts a subsequent, progressive increase in the risk of
death for all causes (Tables 5 and 6, Fig 2); in terms of prognosis in patients hospitalized for
AECOPD, our findings may support the hypothesis of a frequent exacerbator phenotype of
COPD [5,6] which would be of particular relevance in both short and long-term management
and that needing “ad hoc” treatments (use of chronic antibiotics therapy, early rehabilitation
program) or monitoring visit (few days after discharge)Moreover, with regard to the relation-
ship between frequency of AECOPD and mortality in COPD patients, our results corroborate
those of two previous studies published in 2005 [8] and 2014 [21]. In a prospective cohort of
304 stable COPD patients followed up for a period of five years, Soler-Cataluña et al. [8] found
that patients with three or more exacerbations in the initial year had an increased risk of mor-
tality due to all causes in comparison to patients with two exacerbations or fewer; similarly, in a
4-year secondary data analysis of Italian health care administrative databases comprising more
than 15,000 COPD patients, Blasi et al. [21] found that patients with at least one severe
AECOPD within three years prior to the index period had a higher mortality risk than patients
with only moderate or with no episodes of AECOPD. However, neither of those studies report
data on the mortality of patients with early readmission (i.e., within 30 days of hospital
discharge).
Although readmission within 30 days for AECOPD was an independent significant risk fac-
tor in our multivariate model predicting survival at 1 year (Table 8), in agreement with other
studies [8,22,23] we found other clinical risk factors such as higher levels of dyspnea perception
[22] (related to a greater lung impairment) and hypercapnia [8,23] (suggestive of chronic
Table 7. General characteristics of patients lost to follow-up (1 year follow-up).
Variables Patients considered for the study (N = 351) Patients lost to 1-year follow-up (N = 27) p value
Age, years 71.4 ± 10.0 71.2 ± 10.0 0.992
Male 297 (85) 21 (78) 0.349
BMI, kg/m2 27.4 ± 5.5 27.3 ± 5.4 0.866
Smoking habit: Current/No or Former, % 37/63 67/33 0.002
FEV1, % predicted 43.7 ± 16.5 51.2 ± 20.2 0.075
FEV1/FVC 48.8 ± 14.6 46.3 ± 11.9 0.499
GOLD stage: A/B/C/D, % 3/29/49/19 8/46/27/19 0.071
LTOT 100 (28.5) 4 (14.8) 0.125
mMRC baseline dyspnea grade 2 (1; 3) 1.5 (1; 2) 0.017
COPDSS severity questionnaire 14 (9; 19) 10 (5; 14) 0.007
Charlson index 2 (1; 3) 2 (1; 3) 0.558
Use of domiciliary medications
Salbutamol only 12 (4) 0 (0) >0.99
Anticholinergic only 15 (5) 3 (15) 0.087
LABA + Anticholinergic 4 (1) 0 (0) >0.99
LABA + ICS 8 (3) 1 (5) 0.435
Anticholinergic + ICS 4 (1.3) 1 (5) 0.271
LABA + Anticholinergic + ICS 103 (33) 6 (30) 0.759
Abbreviations: see Table 1.
doi:10.1371/journal.pone.0150737.t007
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alveolar hypoventilation and reflecting the severity of the underlying respiratory condition) to
be negative predictors of mortality. In addition, although it has been demonstrated that co-
morbidities have an impact on the short-term and medium-term outcome of AECOPD [24]
and although a previous study [13] found diabetes to be a significant predictor of early read-
mission, we found no correlations or role of co-morbidities in the prognosis of AECOPD. The
incomplete recording of all co-morbidities linked to COPD together may explain this differ-
ence [13].
Major strengths of our research are the prospective and consecutive nature of the data col-
lection, the large cohort of patients enrolled in the long-term follow-up, the statistical
Fig 2. Kaplan-Meier survival curves in the follow-up period: at 30 days (part A), 6 months (part B), 1 year (part C), and 3 years (part D) from
discharge after initial hospitalization.Continuous and dashed lines represent patients with and without 30-day readmission for AECOPD respectively.
doi:10.1371/journal.pone.0150737.g002
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approach, which allows the first evaluation of NNH with readmission as an exposure risk, and
the exclusion of patients with CAP and heart failure.
This study has some limitations. First, it was conducted at a single centre, and so the extrap-
olation of these findings to other settings must be done with care. Second, we lack information
on the cause of death and on the systematic analysis of serum inflammatory biomarkers during
the pre-index stable phase of COPD, at discharge, and at each follow-up visit. Third, no adjust-
ments were made for multiple comparisons. Finally, we cannot rule out the possibility that a
relapse of the initial AECOPD may have been the cause of readmission; as just noted, the lack
of data on serum inflammatory levels at discharge and in the follow-up visit at 30 days in non-
resolving exacerbations [25] did not allow us to confirm our clinical evaluation.
Table 8. Significant univariate andmultivariate Cox regression analyses predicting the probability of death at 1 year.
Variable Univariate Multivariate
HR 95% CI p value HR 95% CI p value
Age 70 y 2.17 1.26–3.74 0.005 - - -
Men 2.13 0.92–4.90 0.077
BMI * 0.041 - - -
Underweight: <18.5 kg/m2 1.07 0.25–4.56 0.92 - - -
Normal weight: 18.5 and <25 kg/m2 1 - - - - -
Pre-obese: 25 and <30 kg/m2 0.42 0.21–0.84 0.014 - - -
Obese: 30 kg/m2 0.44 0.20–0.96 0.039 - - -
Smoking habit † <0.001 - - -
No 1 - - - - -
Current 0.25 0.07–0.91 0.035 - - -
Former 0.94 0.30–3.02 0.92 - - -
Temperature (+1°C) 0.75 0.54–1.03 0.071 - - -
No of exacerbations 2 ‡ 2.26 1.38–3.69 0.001 3.62 1.70–7.70 0.007
No of exacerbations requiring hospitalization 2 ‡ 2.61 1.51–4.52 0.001 - - -
COPD-SS 15 § 4.22 2.47–7.21 <0.001 - - -
Charlson index 3 § 1.66 1.04–2.66 0.034 - - -
mMRC dyspnea score  2 § 5.22 1.84–14.81 0.002 4.71 1.40–15.82 0.012
FEV1 <50% ** 3.29 1.56–6.93 0.002 - - -
FVC <50% ** 2.09 1.16–3.78 0.015 - - -
Haematocrit (+1%) § 0.96 0.92–1.00 0.067 - - -
Haemoglobin (+1 gr/L) § 0.99 0.98–1.00 0.030 - - -
pH (+0.1 units) § 0.70 0.52–0.93 0.015 - - -
PaCO2 (+1 mmHg) § 1.02 1.01–1.03 <0.001 1.02 1.01–1.04 0.005
30-day readmission for AECOPD 2.58 1.57–4.24 <0.001 2.48 1.10–5.59 0.029
LOS (+1 day) 1.06 1.04–1.09 <0.001 - - -
* The p-value corresponds to differences between the four groups (underweight: <18.5 kg/m2, normal weight: 18.5 and <25 kg/m2, pre-obese: 25 and
<30 kg/m2, or obese: 30 kg/m2).
† The p-value corresponds to differences between the three groups (non-smoker, current smoker, or former smoker).
‡ In a period of 1 year prior to index hospitalization.
§ Evaluated at admission for index hospitalization.
** Data evaluated at least 6 months prior to index hospitalization.
Abbreviations: see Tables 1, 2 and 5.
doi:10.1371/journal.pone.0150737.t008
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Conclusion
In hospitalized AECOPD patients, readmission due to an acute exacerbation within 30 days of
discharge is associated with a progressive increase in the long-term risk of death. Moreover, a
history of2 previous exacerbations predicts the 30-day readmission of COPD patients.
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